Additionally, with a broad range of actions, including promotion of insulin synthesis, decreasing GCG production, preservation of pancreatic β-cell mass, decreasing appetite, and gastric emptying, as well as cardio- and neuroprotective functions (29, 30), the GLP-1R is an ideal target for development of treatments for type II diabetes mellitus and obesity. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.